item management s discussion and analysis of results of operations and of financial conditions general bard is a leading multinational developer  manufacturer and marketer of products for the large and growing health care industry 
worldwide health care expenditures approximated trillion in with about half that amount spent in the united states 
bard s segment of this industry  itself a multi billion dollar market  is primarily specialized products used mainly in hospitals  in outpatient centers and in physician s offices to meet the needs of the medical profession in caring for their patients 
the company seeks to focus and concentrate on selected markets with cost effective  innovative products and specialized sales forces to maximize bard s opportunities in managing these markets 
summary results net sales for the full year were billion  which include sales of products that were divested during the year 
full year sales of ongoing products  which include vascular  urology  oncology and surgery products increased to million 
this increase was primarily the result of growth in new and established product lines 
bard s key franchises remain strong 
the company reported record earnings in of million  which include a gain on the sale of its cardiology businesses as well as several other one time items 
without the one time items reported in both and  earnings per share would have shown growth consistent with ongoing sales growth 
results of operations vs 
net sales for totaled billion  which represents a decline from the prior year mostly due to the divestiture of the company s cardiology businesses 
full year sales of ongoing products were million  an increase of over results 
price reductions and the impact of a stronger dollar had the effect of reducing reported net sales by and  respectively 
sales of vascular products rose in radiology and electrophysiology devices showed strong worldwide growth 
graft product sales from our impra division also contributed to the overall growth in the product group 
urology product sales grew in the infection control foley catheter and our proseed brachytherapy business provided the majority of the growth in this area 
sales of oncological products increased in specialty access devices showed good growth  particularly in international markets 
ii results of operations vs 
continued sales of surgery products grew in  propelled by high worldwide growth of mesh products  used primarily for hernia repair 
the product areas discussed above represent substantially all of bard s ongoing products subsequent to the completion of the cardiology divestiture 
net sales by product group for the last three years in millions are vascular urology oncology surgery other ongoing products total ongoing products divested products net sales    sales in the united states of ongoing products rose to million 
the vascular and surgery products provided the greatest growth 
ongoing product sales outside the us increased to million with growth demonstrated by urology  oncology and surgery products 
the impact of a stronger dollar had the effect of reducing these sales by 
the geographic breakdown of ongoing product sales for the last three years is united states europe japan other global pricing pressures together with the additional expenditures related to bard s ongoing manufacturing restructuring effort increased cost of goods sold as a percent of sales to from in in the fourth quarter when a substantial portion of the cardiology sale was completed  bard reported improved cost of goods sold as a percent of sales of from in the prior year quarter 
marketing  selling and administrative expenses declined in as a percent of sales  these expenses increased due to the effect of several one time items such as year expenditures 
reported research and development expense declined as a result of the sale of the cardiology businesses  while bard s spending on its ongoing products was consistent with the prior year 
ii results of operations vs 
continued interest expense declined in due to bard s decision to utilize a portion of the proceeds from the sale of the cardiology businesses to repay short term debt 
in addition  the company elected in june to prepay a long term note which further reduced interest expense 
as a result of a series of strategic initiatives  the company has divested several cardiology product lines 
these transactions closed in the fourth quarter when the company recorded a pretax gain of million 
please refer to note  acquisitions and dispositions  of the notes to consolidated financial statements on page ii for additional information 
please refer to note  other income expense  net  of the notes to consolidated financial statements on page ii of this report for a summary of items in this category in the last three years 
included in this category in are a net gain of million from the settlement of various patent infringement and legal claims and a charge of million for the writedown of assets primarily associated with divested businesses 
income tax the effective tax rate was in  in and in the increase in is largely the result of the sale of the cardiology businesses 
net income in  bard reported net income of million and diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiology businesses of  the net after tax loss from one time items of and the after tax impact of the year costs of diluted earnings per share would have been 
in  bard reported net income of million and diluted earnings per share of 
excluding the net after tax loss from one time items of and the after tax impact of the year costs of  diluted earnings per share would have been 
in  bard reported net income of million and diluted earnings per share of 
excluding the net after tax loss from one time charges of and a reversal of tax reserves of  diluted earnings per share would have been 
results of operations vs 
net sales rose to billion 
products divested in reduced the growth in sales by 
price reductions totaled about and the stronger dollar reduced reported net sales by 
ii results of operations vs 
continued sales of vascular products rose in radiology devices and a full year of sales of graft products from the acquisition of impra  inc both contributed to the growth rate of vascular products 
urology product sales grew in the infection control foley catheter and the contigen bard s collagen implant provided the growth in this area 
sales of oncological products increased in both specialty venous access devices and biopsy products showed strong performance 
sales of surgery products grew in  propelled by high worldwide growth of mesh products  used primarily for hernia repair 
the product areas discussed above represent substantially all of bard s ongoing products 
the combined growth of ongoing products was in sales in the united states of ongoing products rose in to million 
vascular and surgery products provided the best growth in the us sales outside the us of ongoing products increased to million in sales of vascular grafts helped by the acquisition of impra in  specialty access devices  mesh products and basic urological drainage devices contributed to this growth internationally 
bard s cost of goods sold improved to of sales compared with in the company s efforts to reduce manufacturing costs and the acquisition of impra resulted in this improvement 
marketing  selling and administrative expenses increased almost in primarily due to a full year of spending associated with the impra acquisition and the costs associated with programming changes for the year these expenses grew faster than sales and were at a level of of sales in compared with in spending for research and development increased in to of sales from of sales in this increase in spending reflected the continued high cost of competing in the cardiology marketplace 
additional interest expense for the full year related to acquisitions in and resulted in the increase in total interest expense for the year 
ii results of operations vs 
continued other income expense  net  in included charges of million for a manufacturing restructuring plan and million associated with the impairment of investments and intangible assets  and a legal settlement 
these charges were partially offset by gains of million on the sale of the surgical suction and irrigation product line and million from sales of other product lines and assets 
in addition  costs of million in to combine the operations of acquisitions affected income in that year 
the effective tax rate was in and in the lower tax rate in was primarily due to the increased tax benefit in the us related to one time charges and the reversal of approximately million in tax reserves no longer required 
the tax benefit from operations in ireland and puerto rico favorably affected the tax rate in each year 
net income decreased to million in from million in both years were affected by one time items as discussed earlier in this review year functionality bard has a company wide initiative to address year functionality 
a team of management and technical representatives oversees the year efforts 
the company divides its year initiative into two components  information technology it and non information technology non it 
the it initiative includes purchased and internally developed mainframe and desktop computer systems and applications 
the non it initiative includes suppliers  manufacturing and support systems and the company s customers 
internal and external resources are being used to identify needs  make the required it modifications and test year functionality 
the identification process of all critical it applications is complete 
the company is currently on schedule to complete the implementation of all modifications to these applications by the third quarter of the company is utilizing both internal and external resources to provide independent system verification and validation of year functionality 
this process will continue through the end of and includes the development and implementation of contingency plans to address unforeseen problems 
the company s non it efforts include ensuring suppliers  manufacturing and support systems and the company s larger customers are year functional 
the company is communicating with suppliers that provide critical products or services and customers 
the company is testing significant manufacturing and ii year functionality continued support systems 
if as a result of the company s communications or as a result of the company s testing of non it systems there appear to be potential year functionality problems  additional contingency plans under development should minimize these risks 
there can be no guaranty that the systems of other companies on which the company s systems rely will be converted in a timely manner  or that a failure to convert by another company  or a conversion that is incompatible with the company s systems  would not have a material adverse effect on the company 
in addition  there are many risks associated with the year issue  including but not limited to the possible failure of the company s computer and information technology systems 
any failure by a supplier  customer or other entity may have a material adverse financial or operational effect on the company 
the company s marketing  selling and administrative expense included million for it related year expenditures in and million in management believes that the company will incur additional expenses of approximately million in these incremental costs do not include existing internal resources allocated to the project effort 
these costs and the date on which the company plans to complete the year modification and testing processes are based on management s best estimates  which were derived utilizing numerous assumptions of future events including the continued availability of certain resources  third party modification plans and other factors 
however  there can be no guaranty that these estimates will be achieved and actual results could differ from those plans 
financial condition and liquidity bard s financial condition substantially strengthened in the company received proceeds of approximately million from the fourth quarter sale of its cardiology businesses 
a portion of these proceeds along with a second quarter intellectual property settlement and ongoing operating cash flow were used to retire debt and repurchase common stock 
as a result  total debt was reduced by million to million at the end of and the ratio of total debt to total capitalization declined to at december  from at december  shareholders equity was reduced in with the repurchase of million of common stock 
the company has a million syndicated  committed credit facility with a group of banks 
the company made no borrowings under this credit facility in the facility expires in june this facility supports a commercial paper program of million 
the company borrows actively under this program 
ii financial condition and liquidity continued in addition to the million committed credit facility  bard maintains uncommitted credit lines with banks for short term cash needs and these lines were used as needed during the last three years 
at december  the unused uncommitted lines of credit totaled million 
the company expects cash flow from operating activities to exceed capital expenditures and dividend payments 
the company believes it could borrow adequate funds at competitive terms and rates  should it be necessary 
the company believes this overall financial strength gives bard sufficient financing flexibility 
total cash outlays made for purchases of businesses  patents  trademarks and other related items were approximately million in  million in  and million in the majority of these investments were for intangible assets  reflecting the premium over book value for these purchases 
the majority of the cash outlays were financed with additional debt with the balance coming from cash from operations 
periodically  the company purchases its common stock in the open market to replace shares issued under various employee stock plans 
in connection with the announced sale of the cardiology businesses  the board of directors in july authorized the purchase from time to time of up to million shares of common stock 
total shares purchases were  in   in  and  in foreign currency risk the company periodically enters into foreign exchange contracts and options to reduce its exposure to fluctuations in currency values 
contracts have been exclusively for the forward purchase of  and options in  currencies in which the company has known or anticipated payments 
these are primarily for intercompany transactions  resulting in a high degree of confidence that the anticipated transactions will take place 
monetary assets of the company held in foreign currencies have relatively short maturities and are denominated in currencies that have not experienced wide short term fluctuations in their equivalent us dollar values 
please refer to note of the notes to consolidated financial statements on page ii of this report for further information about the company s foreign exchange contracts 
ii foreign currency risk continued the company continues to review and monitor the impact of a common european currency on its business 
due to numerous uncertainties  the company cannot at this time accurately estimate the effect one common currency will have on pricing and the resulting impact  if any  on the company s financial condition or results of operations 
currently  management believes that this impact will not be material 
legal proceedings for a discussion of pending legal proceedings and related matters  please see note  commitments and contingencies  of the notes to consolidated financial statements on page ii acquisitions and dispositions for information on the company s acquisitions and dispositions of businesses  please see note  acquisitions and dispositions  of the notes to consolidated financial statements on page ii cautionary statement regarding forward looking information certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally  including without limitation statements regarding the use of net proceeds from the sale of the company s cardiology businesses  statements regarding cost savings from restructuring  and statements regarding the company s future performance  may contain forward looking statements as defined in the private securities litigation reform act of because actual results are affected by risks and uncertainties  the company cautions investors that actual results may differ materially from those expressed or implied 
factors which could cause the actual results to differ materially from expected and historical results include  but are not limited to health care industry consolidation resulting in customer demands for price concessions  competitors attempts to gain market share through aggressive marketing programs  fewer medical procedures performed in a cost conscious environment  the unpredictability of the approval time by the fda or other government authorities to clear medical devices for commercial release  unanticipated product failures  legislative or administrative reforms to the us medicare and medicaid systems or other non us reimbursement systems in a manner that would significantly reduce reimbursements for procedures using the company s medical devices  the acquisition of key patents by competitors that would have the effect of excluding the company from new market segments  the uncertainty of whether increased research and development expenditures will result in increased sales  unpredictability of existing and future litigation including without limitation litigation regarding product liability  ii cautionary statement regarding forward looking information continued uncertainty related to tax appeals and litigation  price increases from the company s suppliers of critical components  foreign currency fluctuations  unanticipated business disruptions from year issues  the risk that the company may not achieve manufacturing or administrative efficiencies as a result of the company s restructuring and or in the integration of acquired businesses or divestitures 
ii 
